2-[(4-二乙基氨基-1,5,7,9-四氮杂双环[4.3.0]壬-2,4,6,8-四烯-2-基)-己基-氨基]乙醇 | 100557-06-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 三唑并嘧啶类
• 中文名称: 2-[(4-二乙基氨基-1,5,7,9-四氮杂双环[4.3.0]壬-2,4,6,8-四烯-2-基)-己基-氨基]乙醇
• 英文名称: 5-diethylamino-7--s-triazolo<1,5-a>pyrimidine
• 英文别名: 5-Diethylamino-7--s-triazolo<1,5-a>pyrimidin；AR 12456；5-diethylamino-7-(N-(n-hexyl)-N-(β-hydroxyethyl)-amino)-s-triazolo[1,5-a]pyrimidine；2-((5-(Diethylamino)-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)(hexyl)amino)ethanol；2-[[5-(diethylamino)-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl]-hexylamino]ethanol
• CAS: 100557-06-0
• 化学式: C₁₇H₃₀N₆O
• 分子量: 334.465
• InChiKey: NWCVGIMEZSWINX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  24
• 可旋转键数：
  11
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  69.8
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• Treating extrapyramidal syndrome using trapidil
  申请人：Sinopia Biosciences, Inc.

  公开号：US10350212B2

  公开（公告）日：2019-07-16

  Disclosed herein are methods, pharmaceutical combinations, or kits for the prevention or treatment of extrapyramidal syndromes, for example, dyskinesia, dystonia, akathisia, or drug-induced Parkinsonism, with the administration of a therapeutic effective amount of Trapidil, a derivative, a metabolite, a prodrug, an analog, or a pharmaceutically acceptable salt thereof.

  本文公开了一些方法、药物组合或试剂盒，用于预防或治疗锥体外系综合征，例如运动障碍、肌张力障碍、肌张力障碍或药物诱发的帕金森氏症，服用治疗有效量的曲吡地尔、其衍生物、代谢物、原药、类似物或其药学上可接受的盐。
• TREATMENTS OF B-CELL PROLIFERATIVE DISORDERS
  申请人：Rickles Richard

  公开号：US20090053168A1

  公开（公告）日：2009-02-26

  The invention provides compositions and methods for the treatment of B-cell proliferative disorders that employ an A2A receptor agonist or one or more PDE inhibitors. The methods and compositions may further include an antiproliferative compound.
• COMBINATIONS FOR THE TREATMENT OF B-CELL PROLIFERATIVE DISORDERS
  申请人：Rickles Richard

  公开号：US20090047243A1

  公开（公告）日：2009-02-19

  The invention features compositions and methods employing combinations of an A2A receptor agonist and a PDE inhibitor for the treatment of a B-cell proliferative disorder, e.g., multiple myeloma.
• BETA ADRENERGIC RECEPTOR AGONISTS FOR THE TREATMENT OF B-CELL PROLIFERATIVE DISORDERS
  申请人：RICKLES Richard

  公开号：US20100009934A1

  公开（公告）日：2010-01-14

  The invention features a method of treating a B-cell proliferative disorder by administering to a patient a BAR agonist, e.g., formulated for administration by a route other than inhalation (such as for oral or intravenous administration), in an amount effective to treat the B-cell proliferative disorder. The BAR agonist may be administered as a monotherapy or in combination with one or more other agents, e.g., a PDE inhibitor, an A2A receptor agonist, or an antiproliferative compound, in amounts that together are effective to treat the B-cell proliferative disorder. The invention further features pharmaceutical compositions and kits including a BAR agonist, alone or in combination with additional agents, for the treatment of a B-cell proliferative disorder.
• Compositions, Methods, and Kits for Treating Influenza Viral Infections
  申请人：Altmeyer Ralf

  公开号：US20110028510A1

  公开（公告）日：2011-02-03

  The present invention provides compositions, methods, and kits for treating or preventing a viral infection (e.g., an infection caused by an influenza virus).